Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-group study of AB-1005 (AAV2-GDNF gene therapy) in moderate Parkinson's disease
jRCT2033260117Phase 2Not yet recruiting
- Sponsor
- Bayer
- Start
- Jul 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ametefgene parvec in Parkinson's disease (PD), sponsored by Bayer. Primary endpoints: Safety - incidence of adverse events and Efficacy - change in normalized Good ON time. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ametefgene parvec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2033260117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260117.